CA
ATXS

Corriente Advisors’s Astria Therapeutics ATXS Stock Holding History

Corriente Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-102,847
Closed -$3.65M – 12
2019
Q4 		$3.65M Buy
+102,847
New +$3.24M 1.96% 8

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Corriente Advisors's ATXS Position: Q1 2020 in Review

Corriente Advisors sold out of Astria Therapeutics (ATXS) in Q1 2020, closing a stake of 102,847 shares — an estimated $3.65M sold.

Corriente Advisors first reported a position in ATXS in Q4 2019 and held it in 1 quarter. The position peaked at $3.65M in Q4 2019. 27 funds tracked by Wall St. Rank hold ATXS as of Q1 2020.

  • Corriente Advisors reported no remaining Astria Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Corriente Advisors sold 102,847 Astria Therapeutics shares in Q1 2020, an estimated $3.65M.
  • Corriente Advisors first reported a position in Astria Therapeutics in Q4 2019 and held it in 1 quarter.
  • Corriente Advisors's Astria Therapeutics position peaked at $3.65M in Q4 2019.
  • 27 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2020.

Based on Corriente Advisors's 13F filing for Q1 2020, filed 18 May 2020.